Flexion Therapeutics, inc (FLXN) Q2 2021 Earnings Call Transcript

·32-min read
Flexion Therapeutics, inc (FLXN) Q2 2021 Earnings Call Transcript

Today's discussion will be led by Flexion's Chief Executive Officer, Dr. Michael Clayman, and he's joined by Melissa Layman, Flexion's Chief Commercial Officer, and Fred Driscoll, Flexion's Chief Financial Officer. On today's conference call, we will be making statements relating to future financial and business performance, market conditions, strategies and other business matters, including expectations regarding revenue, cash utilization, clinical, regulatory and commercial developments and anticipated milestones, which are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting